1. Background {#sec139243}
=============

When toxin-antitoxin (TA) systems were first discovered, they were considered to be a plasmid maintenance mechanism in the post-segregational killing (PSK) phenomenon ([@A26627R1], [@A26627R2]). Toxin-antitoxin systems act through regulation mechanisms consisting of two components: a stable toxin and a labile antitoxin located on the same plasmid or the same loci of the chromosome. When the plasmid is present, it encodes the antitoxin, which attaches to the toxin and inactivates it, ensuring that only the daughter cells that inherit the plasmid survive after cell division. If the plasmid is absent in a daughter cell, the unstable antitoxin is degraded, and the stable toxin kills the daughter cell during PSK ([@A26627R3]). Toxin is always a protein, but antitoxin can be a protein or RNA ([@A26627R4]).

*RelBE* is one of the most-studied TA systems that mediate the stringent response when amino acid concentrations are very low in an environment of *Escherichia coli*. This response eventually causes the bacteriostasis to save the energy, improving the survival of the bacterium ([@A26627R5]). *ParD* is a plasmid antitoxin that forms a dimer in a ribbon-helix-helix DNA-binding structure. It stabilizes plasmids by inhibiting *ParE* toxin in cells that express *ParD* and *ParE*, and regulates its own promoter (*parDE*). Activation of *ParE* toxin leads to inhibited cell division, but not to cell growth ([@A26627R6], [@A26627R7]). The *higBA* locus was first identified in a temperature-sensitive plasmid (Rts1) of *Proteus vulgaris*. It differs from other characterized TA loci because the toxin-encoding gene (*higB*) lies upstream of the antitoxin-encoding gene (*higA*); however, like other TA loci, the antitoxin represses transcription of the operon. There is a weak sequence similarity between *higB, relE*, and *parE*, which provides conflicting evidence about the cellular role of *higB* ([@A26627R8]).

*Pseudomonas aeruginosa* is one of the most commonly considered Gram-negative aerobic bacilli in the differential diagnosis of a number of Gram-negative infections. Consideration of this organism is important because it causes severe hospital-acquired infections, especially in immune-compromised hosts, is often antibiotic-resistant, which complicates the choice of therapy, and is associated with a high mortality rate ([@A26627R9]). TA system genes have been identified in many prokaryotic genomes; however, their role in cell physiology is unclear ([@A26627R10]). A bioinformatics evaluation of 126 bacterial genomes indicated the presence of TA loci genes ([@A26627R11]). The bioinformatics data introduced three TA loci on *P. aeruginosa* PAO1, including *relBE*, *parDE*, and *higBA* ([@A26627R11], [@A26627R12]).

Repetitive element-based PCR (rep-PCR) is a method for the molecular typing of bacterial genomes, examining strain-specific patterns obtained from PCR amplification of the repetitive DNA elements present within bacterial genomes. Three classes of repetitive elements are used for typing purposes: the repetitive extragenic palindromic (REP) sequence, the enterobacterial repetitive intergenic consensus (ERIC) sequence, and the BOX elements ([@A26627R13]).

2. Objectives {#sec139244}
=============

The aim of this study was to characterize three types of TA systems, *parDE*, *relBE*, and *higBA*, among our *P. aeruginosa*clinical isolates.

3. Materials and Methods {#sec139250}
========================

3.1. Bacterial Isolates {#sec139245}
-----------------------

One hundred seventy-four clinical isolates were collected from three medical centers in Ahvaz, southwest Iran: the Golestan and Emam general hospitals (n = 130) and the special burn unit at Taleghani Hospital (n = 44). These clinical isolates were collected from a variety of clinical specimens, such as urine, blood, feces, bronchial washings, sputum, wound swabs, throat swabs, and ulceration swabs. The isolates were identified as *P. aeruginosa* according to their morphology, Gram staining, oxidase test, OF test, pyocianin and pyoverdin production, and growth on cetrimide agar (Merck, Germany) plates. The control strain PAO1 was also examined. Stock cultures were stored in TSB (Merck, Germany) containing 20% glycerol (Merck, Germany) at −80°C.

3.2. DNA Extraction {#sec139246}
-------------------

Isolates were grown in TSB (Merck, Germany) at 37°C overnight, then DNA was extracted using the genomic DNA extraction kit (Bioneer, South Korea).

3.3. ERIC-PCR and BOX-PCR {#sec139247}
-------------------------

Two typing methods (ERIC-PCR and BOX-PCR) were used to genotype the *P. aeruginosa* clinical isolates, in order to study the bacterial genetic diversity within this complex group. The ERIC and BOX primer sequences (Macrogen, South Korea) were used in PCR to detect differences in the number and distribution of these repetitive sequences in the bacterial genome ([Table 1](#tbl35837){ref-type="table"}) ([@A26627R14], [@A26627R15]).

###### Primers Used for Typing *Pseudomonas aeruginosa* Clinical Isolates

  Primer Name   5\'-3\' Sequence                Reference
  ------------- ------------------------------- ----------------
  **ERIC-1**    CAC TTA GGG GTC CTC GAA TGT A   ([@A26627R14])
  **ERIC-2**    AAG TAA GTG ACT GGG GTG AGC G   ([@A26627R14])
  **BOX-1**     CTA CGG CAA GGC GAC GCT GAC G   ([@A26627R15])

PCR amplification was performed in a final volume of 25 μL containing 3 μL of purified total DNA, 8 μL of PCR master mix (containing Taq polymerase, MgC1~2~, dNTPs, and PCR buffer; Amplicon, Denmark), and 2.5 pM of each primer (Macrogen, South Korea). PCR was carried out in a thermal cycler apparatus (PeqStar; PeqLab, Germany) with an initial denaturation step at 95°C for 3 minutes, followed by 35 cycles including denaturation at 94°C for 1 minute, annealing (at 52°C for ERIC-PCR and at 48°C for BOX-PCR) for 1 minute and extension at 72°C for 2 minutes, with a final extension step at 72°C for 5 minutes.

3.4. Detection of TA System Genes and Analysis of Flanking Region Amplification {#sec139248}
-------------------------------------------------------------------------------

Gene-specific internal primers (Macrogen, South Korea) were used to amplify the *relBE*, *parDE*, and *higBA* TA genes, and the intergenic primers (Macrogen, South Korea) were used to amplify the upstream and downstream of the flanking regions. The sequences of the primers used for this purpose are listed in [Table 2](#tbl35838){ref-type="table"} (17).

###### Primers Used for Detection of TA System Genes and Analysis of Flanking Regions in *Pseudomonas aeruginosa* Clinical Isolates

  Primer name         5\'-3\' Sequence              Expected Fragment, bp   Application     Reference
  ------------------- ----------------------------- ----------------------- --------------- ----------------
  **parDE**                                         556                     PCR             ([@A26627R15])
  F                   GCGGCTGACCTGGATTTATC                                                  
  R                   CCAAGCAGTAGCGGATCAATTG                                                
  **relBE**                                         505                     PCR             ([@A26627R15])
  F                   CAGGGGGTAATTTCGACTCTG                                                 
  R                   ATGAGCACCGTAGTCTCGTTC                                                 
  **higBA**                                         469                     PCR             ([@A26627R15])
  F                   CTCATGTTCGATCTGCTTGC                                                  
  R                   CAATGCTTCATGCGGCTAC                                                   
  **parD-UP**                                       679                     PCR, flanking   ([@A26627R15])
                      (+)CGGTGATCTTTGCCAACACTAAG                                            
                      (−)CTTCCGCTCAGCATATGACTC                                              
  **parE-down**                                     676                     PCR, flanking   ([@A26627R15])
                      (+)TGAGTCTTCTGGGGGTGCTG                                               
                      (−)GGAATTCCACACCATCCGC                                                
  **relE-up**                                       548                     PCR, flanking   ([@A26627R15])
                      (+)CCGGAAAAAGCGCGAGAAAGC                                              
                      (−)GGGGGCTGCAATGAGCCTG                                                
  **relB-down**                                     646                     PCR, flanking   ([@A26627R15])
                      (+)GTGCTCATTTTCTGATCAACTTCG                                           
                      (−)GTGACGCTCTCCGACAGCTTC                                              
  **higA-UP**                                       823                     PCR, flanking   ([@A26627R15])
                      (+)GATCCGACCCCTTCCGTCTAAACG                                           
                      (−)GTAGCCGCATGAAGCATTG                                                
  **higB-down**                                     712                     PCR, flanking   ([@A26627R15])
                      (+)CAGGTGGAGAGCGCAGGTC                                                
                      (−)CAATTGTCCCAACGCCTCCTTCG                                            
  **higA-up-PA7**                                   803                     PCR, flanking   ([@A26627R15])
                      (+)GTTTGCCACGTTTGCATGCAG                                              
                      (−)CGCTCAGTTCTGGATGAATCTCC                                            
  **higB-down-PA7**                                 655                     PCR, flanking   ([@A26627R15])
                      (+)GCATCGCCGATTCCAAGTG                                                
                      (−)GCAACGTGTGTTCGTCACC                                                

PCR amplification was performed in a final volume of 25 μL containing 3 μL of purified total DNA, 8 μL of PCR master mix (containing Taq polymerase, MgC1~2~, dNTPs, and PCR buffer; Amplicon, Denmark), and 2.5 pM of each primer (Macrogen, South Korea). PCR was carried out in a thermal cycler apparatus (PeqStar; PeqLab, Germany) with an initial denaturation step at 94°C for 5 minutes, followed by 30 cycles including denaturation at 94°C for 1 minute, annealing at 52°C for 1 minute, and extension at 72°C for 1 minute, with a final extension step at 72°C for 5 minutes.

3.5. Electrophoresis {#sec139249}
--------------------

The PCR products were separated on 1% agarose gels (SinaClon, Iran) in 1X tris/borate/EDTA buffer (SinaClon, Iran). Bands were visualized under UV gel documentation and photographed. ethidium bromide (Merck, Germany) as a stain was added to the agarose gel (SinaClon, Iran) during preparation to give a concentration of 0.2 μl/mL.

4. Results {#sec139251}
==========

The similarities in the band patterns were analyzed by Dice and clustered by UPGMA methods. If any two isolates had 80% similarity in band patterns, they were considered one type ([Figures 1](#fig26377){ref-type="fig"} - [3](#fig26378){ref-type="fig"}). The results of BOX typing are not shown.

![Gel Electrophoresis for ERIC Types of *Pseudomonas aeruginosa* Clinical Isolates From Taleghani Hospital\
M, 100 bp DNA ladder plus (SinaClon, Iran); T lines, isolates from Taleghani Hospital.](jjm-09-01-26627-g001){#fig26377}

![Gel Electrophoresis for ERIC Types of *Pseudomonas aeruginosa* Clinical Isolates From Emam Hospital\
1, 100 bp DNA ladder (Fermentas, Latvia); E lines, *Pseudomonas aeruginosa* isolates from Emam Khomeini Hospital.](jjm-09-01-26627-g002){#fig26379}

![Gel Electrophoresis for ERIC Types of *Pseudomonas aeruginosa* Clinical Isolates From Golestan Hospital\
M, 100 bp DNA ladder plus (SinaClon, Iran); G lines, *Pseudomonas aeruginosa* isolates from Golestan Hospital.](jjm-09-01-26627-g003){#fig26378}

Detection of TA-associated genes carried out by primers was designed according to the homolog genes found in *P. aeruginosa* PAO1. For the 174 *P. aeruginosa* isolates, *relBE* (174/174, 100%) and *higBA* (174/174, 100%) were universal, whereas *parDE* (53/174, 30%) was less prevalent ([Figures 4](#fig26380){ref-type="fig"} - [6](#fig26381){ref-type="fig"}).

![Gel Electrophoresis for Detection of *higBA* Loci in *Pseudomonas aeruginosa* Clinical Isolates\
The expected size was 469 bp. All isolates were positive for these loci. Line 1, 100 bp DNA ladder (Fermentas, Latvia); line 2, negative control; lines 3 -8, positive loci.](jjm-09-01-26627-g004){#fig26380}

![Gel Electrophoresis for Detection of *relBE* Loci in *Pseudomonas aeruginosa* Clinical Isolates\
The expected size was 505 bp. All isolates were positive for these loci. Line 1, 100 bp DNA ladder (Fermentas, Latvia); line 2, negative control; lines 3 - 8, positive loci.](jjm-09-01-26627-g005){#fig26382}

![Gel Electrophoresis for Detection of *parDE* Loci in *Pseudomonas aeruginosa* Clinical Isolates\
The expected size was 556 bp. Only 30% of the isolates were positive for these loci. Line 1, 100 bp DNA ladder (Fermentas, Latvia); line 2, negative control; lines 3, 6, 8, and 11, positive loci; lines 4, 5, 7, 9, and 10, negative loci.](jjm-09-01-26627-g006){#fig26381}

Comparison of the ERIC types of *P. aeruginosa* strains that carried *parDE*, *relBE*, and *higBA* showed that these strains have different band patterns. This indicates that there is no correlation between genome relatedness and carriage of TA systems. For analysis of flanking regions in TA genes, primers were designed based on the conserved sequence in *P. aeruginosa*strains PAO1 and PA7. We then investigated whether the TA genes were located on a plasmid or the chromosome of the *P. aeruginosa*isolates. For this purpose, the presence of a PCR product would suggest a chromosomal location for TA systems. In our *P. aeruginosa*clinical isolates, both flanking regions of the *parDE* genes in all isolates (174/174, 100%), and the flanking regions of nearly all *relBE* genes (170/174, 97%), were amplified. Amplification was observed for the downstream sequence of *higBA* loci (174/174, 100%), as well as for the region upstream of *higBA*, except for 14 strains (160/174, 76%). For these 14 strains, PCR was performed with primers that were designed based on the PA7 reference sequence, but no product was amplified.

5. Discussion {#sec139252}
=============

Multidrug-resistant *P. aeruginosa* (MRPA) is currently one of the major concerns in health care systems, as it causes nosocomial infections in hospitals throughout the world, including in Iran. Japoni et al. have reported that 22% of metallo-β-lactamase-producing *P. aeruginosa* isolates were completely resistant to imipenem, meropenem, piperacillin/tazobactam, ampicillin, and aztreonam ([@A26627R16]), while Moniri and Tavajjohi detected a 30% rate of multidrug-resistant isolates in their study ([@A26627R17]). Therefore, new strategies are needed to solve the problem of MRPA. Recently, some strategies have been based on designing a conjugate vaccine ([@A26627R18]) or combining antibiotics with herbal extracts or other antimicrobials ([@A26627R19]).

One of these strategies could be designing antimicrobials that can target TA systems. Generally, toxin molecules act as negative regulators in cell survival, and antitoxin molecules act as positive regulators. Under stress conditions, interactions between the expression levels of toxin-antitoxin molecules are vital for the life of bacteria; therefore, they are considered potential targets for the development of new antimicrobial agents ([@A26627R20]). Few studies have been done to investigate clinical bacterial strains for the presence and functionality of TA systems. In this study, we used PCR to show that *higBA* and *relBE* are universal in a collection of *P. aeruginosa*clinical isolates, whereas *parDE* was less commonly observed. Our findings concur with and confirm the report by Williams et al. ([@A26627R15]).

Previously, Moritz et al. showed that TA systems are universal in vancomycin-resistant enterococci ([@A26627R21]), and we confirmed this data for *P. aeruginosa*. Hemati et al. reported a 100% prevalence of *relBE* in *P. aeruginosa*clinical isolates, which is the same as our results, but they did not study the *parDE* or *higBA* TA systems ([@A26627R22]). Karimi et al. reported an 85% prevalence of *relBE* in *E.coli* clinical isolates ([@A26627R2]). These results show that TA systems are more prevalent in nosocomial pathogens than was previously believed. However, more studies are needed to confirm, characterize, and explain the prevalence of disparate classes of TA systems in clinical isolates.

Our analysis of the TA flanking regions showed that a chromosomal location was conserved in all strains harboring the *parDE* gene, in almost all strains harboring *relBE*, and in the majority of strains harboring *higBA*. We could not amplify the upstream sequence of the *higBA* gene in 14 strains; however, the downstream sequence of the *higBA* locus was amplified. Therefore, we can conclude that the *higBA* gene is in a chromosomal locus. These results concur with those of Williams et al. ([@A26627R15]). Their conservative genetic structure and universal presence in clinical isolates make TA systems some of the newest and most interesting antimicrobial targets for designing new drugs for use against bacteria such as MRPA. To reach this goal, it is imperative to evaluate the functionality and expression of TA systems in the life cycle of bacteria. This is the first report of the presence of three TA systems (*parDE*, *relBE,* and *higBA*) in *P. aeruginosa* clinical isolates in Iran.
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